Navegando por Palavras-chave "Carcinoembryonic antigen"
Agora exibindo 1 - 5 de 5
Resultados por página
Opções de Ordenação
- ItemAcesso aberto (Open Access)CA72-4 e CEA no soro e no lavado peritonial de doentes com câncer gástrico(Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia - IBEPEGE Colégio Brasileiro de Cirurgia Digestiva - CBCD Sociedade Brasileira de Motilidade Digestiva - SBMD Federação Brasileira de Gastroenterologia - FBGSociedade Brasileira de Hepatologia - SBHSociedade Brasileira de Endoscopia Digestiva - SOBED, 2002-03-01) Mandorwski, Sandra [UNIFESP]; Lourenço, Laércio Gomes [UNIFESP]; Forones, Nora Manoukian [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Background - The treatment and the prognosis of gastric cancer patients depends mainly on clinical stage. Serum and peritoneal tumoral markers levels can be helpful to evaluate individual risk for recurrence. Aims - To evaluate the sensibility of the tumoral markers in the serum and in the peritoneal washing on diagnosis of gastric cancer. Patients and Methods - Forty patients with adenocarcinoma of the stomach (11 stage I or II and 29 III or IV) and 24 patients with benign diseases were studied prospectively. All of them were submitted to laparotomy. Blood and peritoneal washed was collected during surgery before tumoral resection, for determination of CEA and CA72-4. Results - CEA and CA 72-4 serum levels were elevated in 25% and 47,5% respectively. Through the curves ROC, we defined the cut-off values for the markers in washed peritoneal fluid. Through these values CEA and CA72-4 rose in 60% and 57.5% respectively. The values of CEA and of CA 72-4 in the serum and in washed peritoneal fluid were higher in cancer patients stage III and IV. CEA levels in the peritoneal washed fluid were higher in the patients with tumor T3-4. Washed peritoneal CA72-4 differed the control group from the cancer group. Conclusion - CA72-4 was the most sensitive marker in the serum of the patients with gastric cancer. Otherwise in the washing peritoneal fluid the most sensitive marker was CEA. These levels were higher in patients with surpass the serosa and lower in patients with mucosa or muscular tumors.
- ItemAcesso aberto (Open Access)Efeito de citocinas e toxina tetânica na vacinação gênica de tumores que expressam CEA com Scfv6C4(Universidade Federal de São Paulo (UNIFESP), 2017-03-29) Zanetti, Bianca Ferrarini [UNIFESP]; Han, Sang Won [UNIFESP]; http://lattes.cnpq.br/0069955147703693; http://lattes.cnpq.br/3688249051412919; Universidade Federal de São Paulo (UNIFESP)Introduction: Colon and rectum cancers are highly prevalent among men and women, and prevention and treatment are major medical and scientific challenges. Carcinoembryonic antigen (CEA) is the main tumor associated antigen of these cancers. Previously, our group developed a DNA vaccine against CEA-expressing tumors using a CEA surrogate, scFv6.C4, and its efficacy, evaluated in transgenic mice for CEA, showed 40% tumor-free animais by more than 100 days and in the others the survival increase was between 30 and 70% in relation to the non-vaccinated group. Objective: To evaluate the adjuvant effect of IFNy (Interferon Gamma), GM-CSF (Granulocyte Macrophage Colony-Stimulating Factor), FrC (Fragment C of Tetanus Toxin) and IDUA (Alpha-L-Iduronidase) in gene vaccination with scFv6.C4. Methods: C57BU6J-CEA2682 mice were immunized 4 times by intramuscular electroporation with the plasmid uP-PS/scFv6.C4 alone, or in combination with adjuvant vectors expressing FrC, GM-CSF, IFNy or IDUA. Vaccinated animais were challenged by subcutaneous injection of murine colon adenocarcinoma cells, MC38-CEA, and tumor growth was monitored. The humoral andcellular immune responses were accessed by ELlSA, immunocytochemistry, ELlSPOT, cell proliferation and cYt~toxicity assays. Results: Immunization with scFv6.C4 induced anti-CEA antibodies, with titre about 4- fold higher than preimmune serum. When challenged with MC38-CEA cells, approximately half of the immunized animais did not develop tumor during 80 days of observation, and the others had varying degrees of retardation in tumor growth. The adjuvants tested did not lead to a significant increase in antibody titer, however, animais immunized with scFv6.C4 and FrC or IFNy had increased survival. Cellular response assays showed a significant increase in cytotoxic cell response, especially in the animais vaccinated with FrC. Conclusions: Immunization with scFv6.C4 in combination with adjuvants FrC or IFNy elevated antitumor effect via increased cytotoxic cell response.
- ItemAcesso aberto (Open Access)Marcadores tumorais no câncer colorretal(Colégio Brasileiro de Cirurgiões, 2002-04-01) Fernandes, Luís César [UNIFESP]; Matos, Delcio [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Colorectal cancer is a clinical entity of a persistent relevance in clinical practice and its early diagnosis is a determinant factor to obtain better therapeutic results. Tumor markers are helpful means for a better approach to individuals with such neoplasm. In the present review, the authors analyze the phases in which surgical-clinical treatment markers must be used: diagnosis, determination of tumor stage, establishment of prognosis and detection of recurrence. Current and future markers and the consensus on their use are discussed. Causal factors for errors in diagnosis with markers and perspectives of use are also presented.
- ItemSomente MetadadadosPeripheral and mesenteric serum levels of CEA and cytokeratins, staging and histopathological variables in colorectal adenocarcinoma(W J G Press, 2008-11-21) Ivankovics, Ivan Gregorio [UNIFESP]; Fernandes, Luis Cesar [UNIFESP]; Saad, Sarhan Sydeney [UNIFESP]; Matos, Delcio [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)AIM: To evaluate the differences that exist between peripheral and mesenteric serum levels of carcinoembryonic antigen (CEA) and cytokeratins in patients with colorectal adenocarcinoma.METHODS: One hundred and thirty-eight patients with colorectal adenocarcinoma who underwent surgery at Hospital São Paulo (Discipline of Surgical Gastroenterology of UNIFESP-EPM) between December 1993 and March 2000 were retrospectively analyzed. Differences between CEA and cytokeratin (TPA-M) levels in peripheral blood (P) and in mesenteric blood.(M) were studied. Associations were investigated between peripheral and mesenteric levels and the staging and histopathological variables (degree of cell differentiation, macroscopic appearance, tumor dimensions and presence of lymphatic and venous invasion).RESULTS: Differences were observed in the numerical values of the marker levels: CEA (M) (39.10 mg/L +/- 121.19 mg/L) vs CEA (P) (38.5 mg/L +/- 122.55 mg/L), P < 0.05; TPA-M (M) (325.06 U/L +/- 527.29 U/L) vs TPA-M (P) (279.48 U/L +/- 455.81 U/L, P < 0.01. the mesenteric CEA levels were higher in more advanced tumors (P < 0.01), in vegetating lesions (34.44 mg/L +/- 93.07 mg/L) (P < 0.01) and with venous invasion (48.41 mg/L +/- 129.86 mg/L) (P < 0.05). Peripheral CEA was higher with more advanced staging (P < 0.01) and in lesions with venous invasion (53.23 mg/L +/- 158.57 mg/L) (P < 0.05). the patients demonstrated increased mesenteric and peripheral TPA-M levels with more advanced tumors (P < 0.01 and P < 0.01) and in non-ulcerated lesions (530.45 U/L +/- 997.46 U/L (P < 0.05) and 457.95 U/L +/- 811.36 U/L (P < 0.01)].CONCLUSION: the mesenteric levels of the tumor markers CEA and cytokeratins were higher than the peripheral levels in these colorectal adenocarcinoma patients. Higher levels of these biologic tumor markers are associated with an advanced state of cancerous dissemination. (C) 2008 the WJG Press. All rights reserved.
- ItemSomente MetadadadosPreventive DNA vaccination against CEA-expressing tumors with anti-idiotypic scFv6.C4 DNA in CEA-expressing transgenic mice(Springer, 2017) Denapoli, Priscila M. A. [UNIFESP]; Zanetti, Bianca F. [UNIFESP]; dos Santos, Adara A. [UNIFESP]; de Moraes, Jane Z. [UNIFESP]; Han, Sang W. [UNIFESP]Carcinoembryonic antigen (CEA) is expressed during embryonic life and in low level during adult life. Consequently, the CEA is recognized by the immune system as a self-antigen and thus CEA-expressing tumors are tolerated. Previously, we constructed a single chain variable fragment using the 6.C4 (scFv6.C4) hybridoma cell line, which gave rise to antibodies able to recognize CEA when C57/Bl6 mice were immunized. Here, the scFv6.C4 ability to prevent the CEA-expressing tumor growth was assessed in CEA-expressing transgenic mice CEA2682. CEA2682 mice immunized with the scFv6.C4 expressing plasmid vector (uP/PS-scFv6.C4) by electroporation gave rise to the CEA-specific AB3 antibody after the third immunization. Sera from immunized mice reacted with CEA-expressing human colorectal cell lines CO112, HCT-8, and LISP-1, as well as with murine melanoma B16F10 cells expressing CEA (B16F10-CEA). Cytotoxic T lymphocytes (CTL) from uP/PS-scFv6.C4 immunized mice lysed B16F10-CEA (56.7%) and B16F10 expressing scFv6.C4 (B16F10-scFv6.C4) (46.7%) cells, against CTL from uP-immunized mice (10%). After the last immunization, 5 x 10(5) B16F10-CEA cells were injected into the left flank. All mice immunized with the uP empty vector died within 40 days, but uP/PS-scFv6.C4 vaccinated mice (40%) remained free of tumor for more than 100 days. Splenocytes obtained from uP/PS-scFv6.C4 vaccinated mice showed higher T-cell proliferative activity than those from uP vaccinated mice. Collectively, DNA vaccination with the uP-PS/scFv6.C4 plasmid vector was able to give rise to specific humoral and cellular responses, which were sufficient to retard growth and/or eliminate the injected B16F10-CEA cells.